Christophe Caux - Curriculum Vitae#

Education and Degrees

• 1984 DUT, Biology, U La Rochelle
  
• 1987 Ingenior & Master in Biology, U Clermont
  
• 1992 PhD in Immunology, U Lyon
  
• 1999 HDR U Lyon, 1999
  
• 2006 INSERM Research Director

Current position

• 2017 Director of Team “Cancer Immune Surveillance and Therapeutic targeting ”, CRCL
  
• 2019 Director LICL, “Laboratory of Immunotherapy of Cancer of Lyon”, CLB

Academic responsibilities

• 2004 - 2016 C Caux coordination of the cytometry platform
  
• 2011 - 2021 Co-Director of Department “Immunity, Virus & Microenvironment” of CRCL
  
• 2011 WP leader of “Tumor Immune surveillance”, LabEx DEWweCAN coordinated by P Mehlen
  
• 2011 - 2022 WP Leader of “Immune surveillance & escape” LYRICan (INCa SIRIC) coordinated by JY Blay

Editorial boards

• 2002 Associate editor for Journal of Leukocyte Biology
  
• 2013 2018 Associate editor for Cancer Research
  
• 2017 Associate editor for Bulletin du Cancer
  
• 2019 Associate editor for “Cancers” and “Frontiers”

Scientific Societies and Networks

• 2012 Coordinator of LYRIC Immuno-monitoring Network in Lyon
  
• 2017 Member of the UNICANCER Immuno-Oncology group
  
• 2018 Coordinator of the UNICANCER Immunology Task Force
  
• 2019 Founding member of the FITC French ImmunoTherapy of Cancer Society

Expertises and evaluation

• 2000- Referee for and member of national and international funding agencies (EU, ARC, ANR, Ligue, INCa, ITMO cancer…)
  
• 2019- Member of the national scientific committee of “Ligue contre le Cancer”
  
• 2022- Member of the INSERM scientific commission CSS2
  
• Consulting: BMS, PDC-Line, MSD , Roche, AMGEN

Conferences and meeting organization

• 2012 Organisation committee of 8 international conferences
  
• 2012 >60 invitations to international conferences and 10/year invited presentations and seminars
  

Teaching and PhD committees: 30h/year

Scientific production

Author of >190 publications in international scientific journals. H-factor: 73; 6 patents since 2009, 2 licences. (see publication list)

Patents and valorization: filling of >20 patents within Schering-Plough and 6 from my present work in the academia:
Patent-2 licensing to GSK exploring anti-ICOS in human clinical trials
Patent-3&4: Co-authored with Innate-Pharma
Patent-4 licensing to the Spin-off ErVaccine

Major Grants and national and international Networks

From 2007: Coordination of 12 National INCa, 2 ANR, 3 Foundation ARC, 2 European programs